Craif and The Jikei University School of Medicine sign a new study agreement
By developing a body fluid diagnosis test utilizing urinary miRNA, we will aim to implement methods to detect early stage lung cancer, estimation of recurrence, and prediction of drug effects

Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) has entered into a joint study agreement with the Jikei University School of Medicine (Location: Minato-ku, Tokyo, President: Senya Matsufuji). With the conclusion of this agreement, Craif and Department of Translational Research for Exosomes at The Jikei University School of Medicine (lead principal investigator: Yu Fujita) started study for “developing lung cancer humoral diagnosis test using urinary exosomal miRNA”.

■ Outline of the Study
In lung cancer treatment, the sensitivity of existing biomarkers for diagnosis, recurrence prediction, and drug effects prediction is still in its early stage. On the other hand, past studies have shown that cancer-specific exosomal urinary miRNA are secreted in lung cancer patients, which could be applied as a non-invasive diagnostic biomarker in lung cancer. By analyzing non-invasive urine samples, we aim to develop patient-friendly order-made medicine such as ultra-early stage lung cancer detection, post-operative recurrence prediction, and efficacy and side effects of immune checkpoint inhibitors prediction.